Nuclear factor kappa B subunit 1 (NFKB1)

Nuclear factor kappa B subunit 1 (NFKB1) is a pivotal transcription factor that serves as a master regulator of the immune response, inflammation, and cell survival (UniProt, P19838). It is synthesized as a 105 kDa precursor (p105) that undergoes proteolytic processing to generate the active 50 kDa (p50) subunit, which typically forms a heterodimer with RelA (p65) to regulate gene expression (NCBI Gene, 4790). The NF-κB pathway is activated by a wide array of stimuli, including pro-inflammatory cytokines like TNF-α and IL-1, as well as pathogen-associated molecular patterns (StatPearls, NF-kappaB Pathway). Aberrant activation of NFKB1 is a hallmark of many human pathologies, particularly chronic inflammatory conditions and various malignancies, where it drives the expression of anti-apoptotic genes and promotes cell cycle progression (PubMed, PMC3945405). Pharmacological modulation of this pathway is primarily achieved through proteasome inhibitors like bortezomib, which prevent the degradation of inhibitory proteins and the processing of p105 (PubChem, CID 387447). Despite its therapeutic potential, the ubiquitous nature of NF-κB signaling makes it a challenging target, as systemic inhibition can lead to significant side effects, including profound immunosuppression and impaired wound healing (PubMed, PMC2852564).

Other names

p105p50NF-kappa-B1KBF1EBP-1Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

Drugs targeting the NF-κB/NFKB1 pathway primarily function by preventing the nuclear translocation of the active transcription factor complex. Proteasome inhibitors, such as bortezomib, block the degradation of IκB (inhibitor of kappa B) and the processing of the p105 precursor into p50, effectively trapping the complex in the cytoplasm (PubChem, CID 387447). Corticosteroids act by inducing the expression of IκBα and physically interacting with NF-κB subunits to inhibit their transcriptional activity (PubMed, PMID 7479934). Other experimental approaches include IκB kinase (IKK) inhibitors that prevent the phosphorylation-dependent degradation of IκB proteins (PubMed, PMC2852564).